Ranibizumab Versus Aflibercept for CRVO in Young Patients.
- Sponsor
- South Valley University
- Study ID
- NCT05282420
- Phase
- PHASE4
- Status
- Unknown
Conditions
- Non-Ischemic Central Retinal Vein Occlusion With Macular Edema
Eligibility Criteria
- Sex
- ALL
- Age
- N/A - 50 Years
- Healthy Volunteers
- Not accepted
Interventions
- intravitreal injection of Ranibizumab — PROCEDUREintravitreal injection of Anti-VEGF Ranibizumab (Lucentis®; manufactured in the United States by Genentech/Roche)
- intravitreal injection of Aflipercept — PROCEDUREintravitreal injection of Anti-VEGF Aflibercept (Eylea®; manufactured in the United States)
- Ranibizumab — DRUGRanibizumab
- Aflibercept — DRUGAflipercept
Study Details
this study will compare the efficacy and safety of use either Ranibizumab and Aflibercept in treatment of macular edema resulting from non ischemic central retinal vein occlusion in patients younger than 5o years old
Key Dates
- Start date
- Feb 1, 2021
- Status verified
- Mar 2022
- Primary completion
- Apr 1, 2022
- Completion
- May 31, 2022
Study Design
- Enrollment
- 40 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Active Comparator: Ranibizumab groupRanibizumab injection monthly for 3 successive months
- Active Comparator: Aflibercept groupAflibercept injection monthly for 3 successive months
Primary Outcome Measure
Best corrected visual acuity BCVA [ Time Frame: at 12 months post-injection ]